Articles tagged with Rheumatoid Arthritis
Researchers successfully visualized systemic joint involvement in patients with autoimmune arthritis using ultra-low dose total body PET/CT scans. The scans showed high agreement with standard joint-by-joint rheumatological evaluations and a moderate to strong correlation with rheumatological outcome measures.
A study found that aberrant expression of MAO-B causes both peripheral and neuroinflammation in RA patients, leading to joint pain and cognitive impairment. Administering an MAO-B inhibitor called KDS2010 improved both joint inflammation and cognitive function in a RA animal model.
Researchers at National Jewish Health found pirfenidone effective in slowing ILD progression in RA patients, potentially increasing overall survival. The study was the first prospective treatment trial for this condition.
A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.
A new study published in the Journal of the American Heart Association found that individuals with autoimmune diseases are at a higher risk of complications after a heart attack. The research emphasizes the importance of controlling cardiovascular disease risk factors and developing personalized treatment plans for this population.
A study at Washington State University has identified sulfatase-2 as a critical protein driving damage caused by rheumatoid arthritis. The discovery sheds light on molecular processes behind inflammation in the disease and could lead to improved treatments.
A new drug has proven effective in treating rheumatoid arthritis, with results at least as good as the current 'gold standard' treatment. The medication targets a specific messenger molecule involved in inflammation and joint damage, offering a new approach to managing autoimmune disease.
Researchers at Michigan Medicine have discovered a molecular mechanism that drives the disease-causing effects of the most common genetic risk factor for lupus. The study suggests that targeting this new pathway could lead to the development of safe and effective treatments for SLE, an autoimmune disease that affects millions worldwide.
Researchers from the Journal of Internal Medicine outline a strategy for analyzing traditional Chinese medicine's effectiveness against rheumatoid arthritis. The approach involves isolating active components of individual plants and testing them in animal models of the disease.
Women with active rheumatic disease are at risk of hypertension, preeclampsia, and fetal loss during pregnancy. Effective disease management with safe medications is crucial for a successful pregnancy outcome.
A review of scientific evidence concludes that diet has little impact on the progression of osteoarthritis and rheumatoid arthritis. While a healthy diet brings other health benefits, the impact on these diseases is small and not clinically meaningful.
Researchers at Karolinska Institutet discovered that electrical stimulation of the vagus nerve promotes healing in acute inflammation by shifting the balance between inflammatory and anti-inflammatory molecules. This finding opens new avenues for treating inflammatory diseases, including autoimmune and cardiovascular conditions.
Researchers from Arizona State University investigate autoantibodies in healthy individuals, revealing their pervasiveness and role in human health and disease. The findings aim to improve diagnostics and therapeutics for a range of illnesses.
The Mount Sinai Microbiome Lab will use advanced methods to study the microbiome's role in autoimmune diseases such as rheumatoid arthritis and systemic lupus. The lab aims to identify microbial features that can help find more precise matches between diseases and treatments.
Researchers at Queen Mary University of London have identified genes that can predict response to arthritis treatment and paves the way for future drug development. The study found specific gene signatures associated with resistance to current therapies, which could lead to new treatments.
Researchers at Hokkaido University discovered that ATP secreted from sensory neuron-interneuron crosstalk triggers inflammation spread across joints, acting as a neurotransmitter and inflammation enhancer. Blocking this pathway prevents the spread of inflammation.
Researchers at Gwangju Institute of Science and Technology have developed a new bioinformatics pipeline, CRESSP, to investigate the mechanism underlying autoimmune diseases following SARS-CoV-2 infection. The tool identified potential epitopes responsible for COVID-related autoimmune diseases and predicted cross-reactive epitopes of di...
A neural network was trained to differentiate between healthy joints and those with rheumatoid or psoriatic arthritis using finger joint scans. The AI achieved high accuracy rates, detecting 82% of healthy joints, 75% of rheumatoid arthritis cases, and 68% of psoriatic arthritis cases.
Researchers have discovered sequence variants associated with a large increase in risk of seropositive rheumatoid arthritis. The study highlights the potential for repurposing drugs targeting key proteins involved in the JAK/STAT pathway.
A recent study suggests that many older adults with rheumatoid arthritis are not prescribed disease-modifying medications, despite guidelines calling for early and aggressive treatment. Only 45% of patients over 65 were prescribed these medications, highlighting the need to improve prescribing practices among primary care physicians.
Researchers analyzed genomic profiles of over one million cells from 1,000 people, identifying a link between specific genes and immune cell types in autoimmune diseases. The discovery could lead to tailored treatments and refine clinical trials.
A low-fat vegan diet has been shown to improve joint pain in patients with rheumatoid arthritis, as well as reduce inflammation. The study found that participants who followed a vegan diet experienced significant reductions in disease activity scores, swelling, and cholesterol levels.
Research published in RMD Open found a link between long-term exposure to traffic and industrial air pollutants and an increased risk of autoimmune diseases. Exposure to PM10 above 30 µg/m3 was associated with a 12% higher risk of autoimmune disease, while exposure to PM2.5 above 20 µg/m3 was associated with a 13% higher risk.
A new study predicts rheumatoid arthritis progression using a polygenic risk score. The score, generated from genetic variants associated with the disease, significantly differed between severe and non-severe progression groups. Higher scores were linked to higher risks of severe progression, particularly among younger patients.
A team of researchers at MedUni Vienna's Center for Physiology and Pharmacology has discovered a key building block in immune cells that promotes immunotolerance and prevents T-cell attacks on the body's own tissues. The study suggests a potential new cell-based therapeutic approach to slow down autoimmune disease progression.
Patients under immunosuppressive therapy have increased risk of severe COVID-19 disease courses if they don't respond to primary vaccination. A recent study found that a third booster vaccination is safe and effective in these patients, who were initially unable to produce antibodies after vaccination.
A new study found that disease-modifying antirheumatic drugs do not protect people with rheumatoid arthritis from developing Parkinson's disease. However, using chloroquine or hydroxychloroquine was associated with a lower risk of PD. The study controlled for various factors, including comorbidities and age.
A large-scale review of anti-inflammatory drugs used for autoimmune disorders suggests that current treatments can worsen lipid metabolism, leading to increased cardiovascular disease risk. Researchers propose the development of combination therapies targeting lipid metabolism to reduce immune complications and CVD risk in patients.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.
A study published in JAMA Internal Medicine found that people with immune dysfunction, such as HIV infection or rheumatoid arthritis, had a higher rate of COVID-19 breakthrough infections after vaccination. These individuals also experienced worse outcomes compared to those without immune dysfunction.
A study published in Annals of the Rheumatic Diseases found that crAss-like phages, a component of the gut virome, are less abundant in individuals with autoimmune diseases. This discovery may lead to the development of targeted therapies to manage autoimmune conditions.
Researchers at UC Riverside have discovered that targeting the TNFR1 receptor may be a more effective approach to treating inflammatory bowel disease. By selectively blocking TNFR1, they found significant benefits in mice with Crohn's-like ileitis, suggesting this approach could offer a new opportunity for healing.
Researchers used AI and genomic data to predict which patients with early-stage rheumatoid arthritis are most likely to benefit from methotrexate treatment within the first three months. The study identified potential personalized medicine approaches for rheumatoid arthritis treatment, paving the way for further research.
Researchers identified epimutations in cheek cells that can predict rheumatoid arthritis susceptibility. The discovery could lead to a non-invasive diagnostic test for the disease. Biomarkers were found in both Caucasian and African-American women with rheumatoid arthritis, suggesting a strong signal for the disease.
Researchers have linked T cell dysfunction in rheumatoid arthritis to a metabolic deficiency, suggesting a new therapeutic strategy. The study found that supplying the amino acid aspartate may provide a solution by repairing mitochondrial defects and suppressing TNF production.
People taking immunosuppressants, especially TNF inhibitors, have a weaker antibody response to COVID-19 vaccines. A third dose can drive antibody levels back up, but the duration is unknown.
A new study by Boston Children's Hospital researchers found that tissue-resident memory T cells in joints anchor themselves after a flare and wait for another trigger to react. Deleting these cells prevents arthritis flares from occurring, opening up new therapeutic avenues for rheumatoid arthritis treatment.
Researchers at University of Virginia Health System have discovered a new treatment target for osteoporosis and bone loss from rheumatoid arthritis. A cellular protein called ELMO1 promotes the activity of osteoclasts, which break down bone, leading to excessive bone degradation.
Researchers at UToledo have developed a protein-based vaccine that promotes a strong immune response, effectively treating rheumatoid arthritis and improving bone quality. The findings suggest long-term benefits following immunization.
A team of international researchers has unraveled the inner workings of C5aR2, a key receptor involved in inflammation and COVID-19. The study provides an additional opportunity for therapeutic targeting with new drug molecules to block its activation and inflammation response.
A new center will be established at CU Anschutz Medical Campus to investigate rheumatoid arthritis and spondyloarthritis, with the goal of identifying new treatments and preventing disease. The center will combine resources from over 40 researchers and provide funding for graduate students and postdoctoral fellows.
Researchers at Queen Mary University of London have created an experimental model of cardiomyopathy in inflammatory arthritis, replicating symptoms in RA patients. The study identifies a potential therapeutic approach to treat cardiomyopathy in RA patients.
A new study examines the similarities and differences among disease activity indices used to monitor rheumatoid arthritis. Researchers found that while there are high correlations among the indices, they were not interchangeable, highlighting the need for further analysis of RA in patients using various indices.
A study found that hospitalized COVID-19 patients who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care, died less often than those receiving only the standard of care. The COV-BARRIER trial showed a 5% reduction in 28-day and 60-day mortality.
Researchers have genetically engineered cells that can deliver a biologic drug in response to inflammation, reducing inflammation and preventing bone damage in mice with rheumatoid arthritis. This approach could provide personalized treatments for arthritis patients, limiting side effects associated with current therapies.
Researchers at Washington University School of Medicine found that COVID-19 vaccination elicited a response in nearly nine out of ten people with weakened immune systems. However, the responses were only about one-third as strong as those mounted by healthy people. Despite this, the discovery is encouraging news for a population at hig...
A new study found that parental smoking may increase the risk of developing rheumatoid arthritis in children when they reach adulthood. The research, published in Arthritis & Rheumatology, associated parental smoking with a 75% higher risk of developing the disease, even after controlling for personal smoking habits as an adult.
Researchers found that some medications used to treat autoimmune rheumatic diseases can weaken the immune response to COVID-19 vaccines. Vaccination still induced an immune response in patients, but at a lower rate than in those without autoimmune diseases.
Researchers found that combining anti-rheumatic drugs can reduce the risk of cardiovascular disease in rheumatoid arthritis patients. Two specific combinations - tumour necrosis factor inhibitors and hydroxychloroquine - showed promise in preserving endothelial function.
Researchers at NYU Abu Dhabi have determined the structure of a nanobody, Nb23, using liquid state techniques. This breakthrough could lead to better understanding of its disease-fighting potential and exploration of alternative therapeutic uses.
EULAR taskforce develops guidelines to standardize intra-articular injection (IAT) care, emphasizing patient-centered outcomes and contextual factors. The new recommendations aim to improve IAT quality, providing patients with personalized information and support.
Research suggests passive smoking in childhood increases risk of developing rheumatoid arthritis (RA) in women who have never smoked. Adult exposure also linked to RA risk, particularly among non-smoking women. Environmental air pollution may affect treatment outcomes.
A population-based cohort study in Catalonia, Spain, found positive associations between RA and COVID-19 diagnosis and hospitalization. In contrast, no association was observed between RA and worsening from outpatient to hospital or death. Further research is needed to address comorbidities and immunosuppressive medications.
New study finds that elderly RA patients are not at higher risk of serious infections with bDMARDs or JAKi, but glucocorticoid use and underlying diseases increase the risk. Better physical capacity is associated with a lower risk of serious infection.
Women with rheumatoid arthritis (RA) have an increased likelihood of pre-term birth and small babies. High maternal disease activity during pregnancy strengthens these associations. In contrast, paternal inflammatory disease is associated with a higher risk of miscarriage, particularly in pregnancies conceived after the father's diagno...
A study found that baseline use of biologic medications like rituximab and JAK inhibitors is associated with worse COVID-19 outcomes in people with rheumatoid arthritis. This association was seen even after adjusting for potential confounding factors.
Studies of people with RA show a decline in dementia risk over time, from 12.7% to 6.2% between the 1980s and 2000s. Heart failure risks also decrease, with no excess risk seen in 2000s compared to general population.
A study using Finnish data found that the MUC5B promoter variant is a strong predictor of developing interstitial lung disease in people with rheumatoid arthritis, with a lifetime risk of 14.5% by age 80. The risk difference starts to emerge at age 65 and is highest in men with RA who are MUC5B carriers.
A study of 300 rheumatism patients found 9% SARS-CoV-2 antibody positivity rates for IgG, IgM, and IgA, with higher titres in symptomatic patients and those with obesity and multiple comorbidities. The study confirms that the true spread of SARS-CoV-2 infection is broader than previously thought, particularly among vulnerable populations.
A study of 2837 people with RA found that patients with low empowerment had worse pain, function, and quality of life over time. Remote management technologies, such as patient self-assessment and outcome measures, showed fair agreement with clinical decisions.